PROKERA®

START EARLY **FINISH STRONG**



Early intervention with PROKERA supports restoration of the cornea's own healing capabilities, reducing inflammation, improving corneal health, and optimizing long-term outcomes.[1-7]

biotissue
A TissueTech Company

For patients with ocular surface disease

CORNEAL HEALING **IS CRUCIAL**[1,8]

Impaired corneal healing increases risk of[8]:

- Repeated epithelial defects or erosions
- Chronic inflammation
- Scarring
- Vision loss
- Pain

The Challenge with Conventional Treatments

Corticosteroids

Increased ocular pressure, cataract formation, and infection risk[1,9]

Eye Drops

Ocular surface changes, inflammation, and fibrosis[10]
May rely on a single molecule to address inflammation in multifactorial diseases[11,12]

Bandage Contact Lenses

No therapeutic benefits, relies on body's ability to heal itself

Prolong re-epithelialization and corneal healing[1-3,9,10]

PROKERA®

Kick-Start Corneal Healing With PROKERA®[1]

PROKERA—the only FDA-cleared cryopreserved amniotic membrane—supports the corneal-healing process without harmful side effects.[1,4,6]

- Retains Cryopreserved Amniotic Complex™, HC-HA/PTX3: Proprietary CryoTek® preservation method maintains full biologic and structural integrity equivalent to fresh tissue[13,14]
  - **— Alternative amniotic membrane solutions that are dehydrated lack crucial biologic components[14]**
- Helps rapidly restore the cornea's own healing capabilities with key Cryopreserved Amniotic Complex, the essential effector complex that orchestrates regenerative healing[5]

FACILITATES

neutrophil apoptosis, polarizes M2 macrophages, and suppresses Th1 and Th17 lymphocyte activation to reduce inflammation[7]

PREVENTS

myofibroblast differentiation to prevent scarring[7]

MAINTAINS

stem cell quiescence to promote regenerative healing[7]

Meets the highest quality standards:

An AATB accredited tissue bank, Bio-Tissue® is the only ISO† certified manufacturer of amniotic membrane products*

*AATB = The American Association of Tissue Banks.
†ISO = International Organization for Standardization.

EFFECTIVE **EARLY INTERVENTION**[1,2,4,6]

Demonstrated Effectiveness

- Reduces harmful inflammation[1,2]
- Minimizes scarring[2,4]
- Achieves corneal clarity[1]

Supporting Superior Outcomes

- Recent studies suggest improved corneal nerve regeneration and accelerated ocular-surface health recovery[2,3,5]
- Same studies demonstrate significantly improved corneal nerve density and sensitivity ($P = 0.015$; $P < 0.001$)[2,*]
- Halts fibrosis, facilitating faster re-epithelialization[1,6]
- Superior outcomes vs bandage contact lens (BCL)[1,†]:
  - 70% of eyes re-epithelialized by day 5 with PROKERA Slim vs only 20% with BCL
  - 90% of eyes achieved absolute corneal clarity by Day 7 with PROKERA Slim vs 0% with BCL



(a)



BEFORE PROKERA*



AFTER PROKERA*

After PROKERA photo taken three months after treatment. Standard treatment window for PROKERA is 3-7 days.

Supported by over 360 peer-reviewed publications and 20+ years of proven clinical performance.

PROKERA®

Across a Range of Applications

Over 300,000 PROKERA applications for moderate-to-severe cases of:

Delayed Healing	• Neurotrophic keratoconjunctivitis • Exposure keratoconjunctivitis	• Punctate keratitis • Filamentary keratitis
Dystrophy	• Epithelial corneal dystrophy	• Recurrent corneal erosions
Degeneration	• Band keratopathy	• Nodular corneal degeneration
Defects	• Corneal ulcers • Central corneal ulcer • Corneal ulcer with hypopyon	• Marginal corneal ulcer • Mycotic corneal ulcer • Dendritic corneal ulcer
Damage	• Chemical burn • Thermal burn	• Acid burn • Steven-Johnson Syndrome

References: 1. Desai NR. A comparison of cryopreserved amniotic membrane and bandage contact lens in their ability to provide high-quality healing after superficial keractectomy. *Rev Ophthalmol.* September 2014:1-6. **2.** John T, Tighe S, Sheha H, et al. Corneal nerve regeneration after self-retained cryopreserved amniotic membrane in dry eye disease. *J Ophthalmol.* 2017:6404918 (Epub). **3.** McDonald MB, Sheha H, Tighe S, et al. Treatment outcomes in the DRy Eye Amniotic Membrane(DREAM) study. *Clin Ophthalmol.* 2018;12:677-681. **4.** Pachigolla G, Prasher P, Di Pascuale MA, et al. Evaluation of the role of PROKERA in the management of ocular surface and orbital disorders. *Eye Contact Lens.* 2009;35(4):172-175. **5.** Cheng AM, Zhao D, Chen R, et al. Accelerated restoration of ocular surface health in dry eye disease by self-retained cryopreserved amniotic membrane. *Ocul Surf.* 2016;14(1):56-63. **6.** Morkin MI, Hamrah P. Efficacy of self-retained cryopreserved amniotic-membrane for treatment of neuropathic corneal pain. *Ocul Surf.* 2018;16(1):132-138. **7.** Tseng SC. HC-HA/PTX3 purified from amniotic membrane as novel regenerative matrix: Insight into relationship between inflammation and regeneration. *Invest Ophthalmol Vis Sci.* 2016;57(5):1-8. **8.** Rumpakis J. Amniotic membranes—the perfect cover. *Rev Ophthalmol.* April 2016:49-54. **9.** Baudouin C, Irkeç M, Messmer EM, et al. Clinical impact of inflammation in dry eye disease:proceedings of the ODISSEY group meeting. *Acta Ophthalmol.* 2018;96(2):111-119. **10.** Baudouin C , Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. *Prog Retin Eye Res.* 2010;29(4):312-334. **11.** Abidi A, Shukla P, Ahmad A. Lifitegrast: A novel drug for treatment of dry eye disease. *J Pharmacol Pharmacother.* 2016;7(4):194-198. **12.** Colligris B, Alkozi HA, Pintor J. Recent developments on dry eye disease treatment compounds. *Saudi J Ophthalmol.* 2014;28(1):19-30. **13.** Tan EK, Cooke M, Mandrycky C, et al. Structural and biological comparison of cryopreserved and fresh amniotic membrane tissues. *J Biomater Tissue Eng.* 2014;(4):379–388. **14.** Cooke M, Tan EK, Mandrycky C, et al. Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. *J Wound Care.* 2014;23(10):465-476. **15.** Data on file, Bio-Tissue.

93% of patients with moderate- to-severe dry eye disease reported improvement after one PROKERA treatment.[15]

A family of solutions. To meet your patients' needs.

PROKERA® Slim

ComfortRING™ slim profile contours to the ocular surface for patient comfort

PROKERA®

Ideal for maintaining orbital space when prevention of closure or adhesions is required

PROKERA® Clear

Clear-View™ 6mm aperture is designed for monocular needs and for maintaining some visual clarity during application

PROKERA® PLUS

Doubled cryopreserved amniotic membrane provides an extra layer of tissue for patients needing more intensive therapy

Integration Made Easy

PROKERA can be easily incorporated into any eye care practice to optimize outcomes.

EFFECTIVE, EASY TREATMENT

- Can be easily placed during a regular office visit or used with surgical interventions
- May reduce the need for additional visits for slow-or poor-healing patients

HIGHLY REIMBURSED

- Medical device classification ensures high reimbursement
- Average Medicare reimbursement: $1,458
- Minimizes a patient's cost-burden of treatment

MINIMAL STORAGE NEEDS

- Minimal packaging
- Conveniently stored in any onsite refrigerator or freezer

PROKERA®

*In a prospective, randomized clinical trial of 20 patients with dry eye disease. Corneal nerve density in the PROKERA Slim group (n=10) increased from 12,241 ± 5083 µm/mm^2 at baseline, to 16,364 ± 3734 µm/mm^2 at 1 month, and to 18,827 ± 5453 µm/mm2 at 3 months (P = 0.015), but was unchanged in the control (n=10). Corneal sensitivity increased from 3.25 ± 0.6 cm at baseline, to 5.2 ± 0.5 cm at 1 month, and to 5.6 ± 0.4 cm at 3 months (P < 0.001) with corneal topography only in the PROKERA Slim group.

†In a comparative study of 10 patients post-superficial keratectomy, who had either bilateral recurrent erosion syndrome, epithelial basement membrane disease, or Salzmann nodule degeneration. The eye with more severe disease was treated with PROKERA Slim and the less severe eye was treated with BCL.

For greater patient satisfaction, start with PROKERA today.

biotissue®
A TissueTech Company

7300 Corporate Center Dr., Suite 700, Miami, FL 33126 • 888.296.8858 • www.biotissue.com US-PK-1900008 Rev. 01 9/19